CeriBell (NASDAQ:CBLL) Sets New 1-Year High After Analyst Upgrade

Shares of CeriBell (NASDAQ:CBLL) hit a new 52-week high during mid-day trading on Monday after TD Cowen raised their price target on the stock from $31.00 to $36.00. TD Cowen currently has a buy rating on the stock. CeriBell traded as high as $31.82 and last traded at $31.82, with a volume of 9376 shares traded. The stock had previously closed at $30.24.

A number of other equities analysts also recently issued reports on the company. Canaccord Genuity Group started coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price for the company. JPMorgan Chase & Co. assumed coverage on CeriBell in a research note on Tuesday, November 5th. They set an “overweight” rating and a $32.00 target price for the company. Bank of America initiated coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective for the company. Canaccord Genuity Group lifted their price objective on CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Monday. Finally, William Blair assumed coverage on CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $32.60.

CeriBell Trading Up 1.2 %

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. On average, analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.